The RevSpan Weekly
The RevSpan Weekly
An operator's read on GTM and Revenue Operations. For CROs, CEOs, CFOs, and the operating partners who hold them accountable.
The Seat Is Dying. Your Forecast Hasn't Noticed.
Mid-April brought a noticeable rotation back into beaten-down cloud names after the 18-month "SaaS Apocalypse." Constellation, FinancialContent, and IndexBox all marked April 15 as the bottom — but the recovery is not a return to the old model. It's a re-rating around a different one.
The headline shift: seat-based licensing is being replaced by "Agentic Work Units" and performance credits. CIO adoption of agentic production environments was up 280% year-over-year by end of Q1. The winners (Oracle, ServiceNow, Ares) sit on top of customer data and workflows. The losers are SaaS UI wrappers — companies whose moat was the screen, not the system of record.
If your comp plan, capacity model, and forecasting framework still assume revenue is a function of seats × ARPU × retention, you're modeling a world that's eroding. The hard question for any CRO right now: what is the unit of value our customer pays for next year, and what's the rep's role in selling it?
You don't need to solve this in Q2. You do need a working group on it before annual planning starts. Companies that show up to the FY27 board meeting with a usage/hybrid forecast model and a coherent story about how reps still drive growth in an agent-priced world will get rewarded. Everyone else gets the "you're behind" question from the ops partner.
MEDDIC + Command of the Message: The Hybrid Stack Wins
Sales Assembly's 2026 methodology benchmark and a wave of practitioner content this week converged on the same conclusion: the most sophisticated enterprise orgs are running hybrids, not picking sides. 73% of SaaS companies selling $100K+ ARR use a MEDDIC variant. Pair it with Command of the Message — and let AI extract both frameworks from a single conversation — and the data shows 2.8x win rate lift.
Meanwhile, academic researchers are calling this combined behavior something new — "Holistic Selling" — where the rep's job is no longer order-getting or relationship-tending, but orchestrating the buyer's purchase journey across human, digital, and AI touchpoints.
Stop arguing about which methodology to pick. The question isn't which methodology — it's which one actually gets coached. Across the dozens of sales orgs I've worked with that "ran MEDDIC," only a handful had the MEDDIC fields populated in CRM with a manager review cadence behind them. The rest had a sticker on a laptop and a kickoff deck from 2023.
Pick the framework you'll inspect every week — every pipeline review, every 1:1, every QBR. The methodology doesn't drive the lift. The cadence does. (Garbage in, garbage out — and unread MEDDIC fields are garbage by another name.)
Stack Consolidation Around an AI Intelligence Layer
The 2026 RevOps stack has settled into three layers: Input (Salesforce, Gong, ZoomInfo, 6sense), Intelligence (where MEDDPICC evidence is auto-extracted and deal health is scored), and Execution (AI populates CRM, runs deal reviews, produces forecasts, coaches reps in real time). Aviso, LeanData, and Glean all published versions of this taxonomy this month.
The notable cross-stack development: MCP (Model Context Protocol) is now letting AI agents read and write across the full tech stack — updating CRM records, creating tasks in project management tools, generating handoff docs in Notion.
The "23% lower spend / 18% better attainment" stat is the most-cited and most-misused number in RevOps right now. Reality check: most consolidation projects fail because they rip out the wrong tool. The expensive one isn't always the broken one.
Before you cut your stack, run a 30-day adoption audit — what are reps actually opening daily? What are managers actually inspecting in? The expensive tool nobody opens is the obvious cut. The cheap tool nobody opens is the one that exposes your enablement problem. Don't skip step two — that's where the actual savings live, and where most leaders flinch.
The Revenue Enablement Category Just Got Capitalized
Two notable raises this month put a stake in the ground on AI-native revenue tooling:
Letter AI (Chicago) — $40M Series B led by Battery Ventures, with Y Combinator, Lightbank, Northwestern Mutual Future Ventures, and Stage 2 Capital. AI-native revenue enablement.
Actively AI — $45M Series B for its AI sales platform.
Zoom out: AI-native startups now account for 28% of all North American Series A/B deals, up from 12% in 2022. The shift is unmistakably toward platforms that operationalize AI in production environments — not experiments, not demos.
Battery, Y Combinator, and Lightbank don't all show up in the same month by accident. They're betting that revenue enablement consolidates around AI-first architecture in the next 24 months — and that the incumbents (Highspot, Seismic, Showpad) either rebuild on top of it or get re-rated.
If you're a CRO at a Series B+ company and you don't have a defined enablement function, you're now competing against teams who can stand up territory plays, battlecards, and seller coaching faster than you can hire. That's a buy-vs-wait decision — and "wait" is no longer a free option. Pick a posture before your board picks one for you.
The Medallia Wipeout Is the Lesson Every Portco Should Read
Two PE stories dominated the SaaS press this month:
Thoma Bravo / Medallia — Reuters reported on April 22 that Thoma Bravo is near handing Medallia over to creditors, effectively wiping out roughly $5.1 billion in equity value. One of the largest equity impairments in software buyout history.
Thoma Bravo strategic shift — TB is winding down its growth equity arm to refocus on buyouts, and was reportedly exploring a Commvault acquisition (April 10).
Counterweight from the operating side: portfolio companies that execute disciplined 100-day plans deliver 2-3x better revenue growth in year one. Companies running commercial excellence playbooks are hitting 34% ARR growth (vs. 12% baseline), 115% NRR, and 1.8x exit multiples.
Medallia is the shadow over every PE-owned SaaS asset right now. The lesson isn't "don't take PE money" — that ship has sailed for most of this audience. The lesson is that operating partners have less patience than they did 18 months ago for "we're still building the model" answers.
If your operating partner asks you "what's your forecast confidence interval, and how would you know it's wrong?" and you don't have a clean answer — you're already losing the room. The 34% ARR growth stat is the upside. The Medallia number is the downside. The middle ground is shrinking. PE-backed CROs who treat the next 90 days as a tightening of forecast discipline, ICP discipline, and comp discipline will outrun the ones who don't.
The Buyer Already Did Discovery. Without You.
The current issue of the Journal of Personal Selling & Sales Management (Vol. 46, No. 1) is one of the more relevant academic releases for practitioners in a while. Two papers stand out:
"Holistic Selling: An Emerging Paradigm in B2B Markets" (Kalwey, Krafft, Lim, Mantrala) — argues the rep's role has shifted from order-getting and relationship-building to orchestrating the buyer journey across all touchpoints.
"Unpacking Generative AI for B2B Sales" — introduces the AGA framework (Autonomy, Generativity, Adaptability) for classifying GenAI sales roles as sociotechnical systems.
The killer stats from related buyer-behavior research, courtesy of Corporate Visions and Consensus:
85% have largely established their purchase requirements before speaking to a salesperson.
That 91/85 pair is the most important statistic in this newsletter. It rewrites what "discovery" means. If 85% of your buyers have already established requirements before they meet your rep, then asking them to articulate their pain isn't discovery — it's annoyance. They've already done that exercise with three vendors and an AI assistant.
Modern discovery is diagnosis: "you've done the homework, here's what you might have missed and here's the consequence of missing it." That's a different rep, a different enablement program, and a different management cadence than what most orgs are running. If your discovery call still opens with "tell me about your business," you're training your buyers' patience — and burning the goodwill you spent six demand-gen channels acquiring.
Reading this and recognizing your own quarter?
RevSpan Advisors runs fixed-fee 30-day Diagnostic Sprints for B2B companies between $10M and $100M ARR — Forecast Architecture, ICP & Pipeline Quality, Comp Plan Audit, or Capacity Model. Every Sprint produces a findings deck and a recommended path forward.
Book a Discovery Call